Target intelligence / Profile preview

Nuclear transcription factor Y subunit alpha (NFYA)

Target
NFYA
Molecular classification
Transcription factor, Sequence-specific DNA binding protein, Trimeric protein complex subunit, Histone fold-containing protein
01

Overview

Nuclear transcription factor Y subunit alpha (NFYA) is an essential component of the highly conserved NF-Y trimeric transcription factor complex, together with NF-YB and NF-YC[1][4][5][2][7]. The NF-Y complex specifically recognizes and binds to CCAAT box motifs found in the promoters of a wide array of genes, acting as a sequence-specific DNA binding factor and a pioneer factor that increases chromatin accessibility for other transcription regulators[1][2][4]. NFYA provides the sequence specificity and regulatory function of the complex, contains a glutamine-rich transactivation domain, and participates in transcriptional regulation critical for cell cycle control, DNA damage response, and proliferation[4][1][5]. While implicated in cancer and other diseases through its regulation of gene expression, NFYA is not a direct therapeutic target in current clinical practice.

Other names
NFYANF-YAHAP2CBF-BCAAT box DNA-binding protein subunit ANuclear transcription factor Y subunit ACBF-ACCAAT-binding transcription factor subunit BHAP2 CCAAT-binding proteinTranscription factor NF-Y, A subunitCCAAT-box DNA binding protein subunit A
02

Biological functions

Regulation of transcriptionPromotion of chromatin accessibility (pioneer factor activity)Transcription start site selectionCell cycle regulationResponse to DNA damageRegulation of endoplasmic reticulum stressTissue-specific and isoform-specific gene expression control
03

Disease associations

Cancer (NF-Y complex implicated in cell proliferation, transcriptional activation of oncogenes)Other (potential involvement in various stress responses and transcriptional regulation-related diseases, but no direct drug targeting known)
04

Safety considerations

Targeting a ubiquitous transcription factor may yield broad gene expression changes, risking off-target effects and toxicity.Potential for interference with essential cellular processes including cell cycle progression, apoptosis, and response to stress.

Beyond the preview

Go deeper on Nuclear transcription factor Y subunit alpha (NFYA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear transcription factor Y subunit alpha (NFYA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call